Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.38 |
| ▸ | PDE1A | P54750 | 4/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25690929 | 0.89 | PDE1B (0.34) | MAPK1PDE1BPIK3C3 | |
| SCHEMBL25690928 | 0.82 | NPC1 (0.37) | KDM5BHPGDS | |
| SCHEMBL19862537 | 0.82 | NPC1 (0.40) | MAPK1HPGDS | |
| SCHEMBL6633135 | 0.81 | NPC1 (0.42) | CSF1RHPGDS | |
| SCHEMBL8489672 | 0.79 | HPGDS (0.48) | HPGDS | |
| Hydrochloric Acid SCHEMBL22468947 | 0.78 | HPGDS (0.47) | HPGDS | |
| SCHEMBL21453769 | 0.77 | PDE1B (0.34) | MAPK1PDE1BPDE1APDE1CDAO | |
| SCHEMBL15893921 | 0.77 | CASP3 (0.34) | MAPK1PDE1BPDE1APDE1CCSF1R | |
| SCHEMBL22860618 | 0.76 | PARP1 (0.44) | HPGDS | |
| SCHEMBL19398933 | 0.75 | PDE1B (0.35) | MAPK1PDE1BPDE1APDE1CDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023088493-A1 | FURO-PYRIDONE COMPOUND AND USE THEREOF | 中国科学院广州生物医药与健康研究院 | 2023-05-25 | — | — | WO | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273985-A1 | TRICYCLIC DERIVATIVE | PDE3A, PDE2A, PDE5A | MAPK1 2891/4885PDE1B 15/4885PDE1A 13/4885 |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | MAPK1 1503/4885PDE1B 17/4885PDE1A 14/4885 |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | MAPK1 2211/4885PDE1B 1585/4885PDE1A 1780/4885 |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE4B, PDE12 | MAPK1 3550/4885PDE1B 12/4885PDE1A 9/4885 |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | PDE3A, PDE2A, PDE5A | MAPK1 2274/4885PDE1B 19/4885PDE1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.